Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 3.19 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 3.19K shares, a 97.16% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 13.80K shares.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 237.18K shares, a 39.26% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 390.49K shares, a 601.43% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 55.67K shares, a 719.76% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 6.79K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 3.19K shares 10-Q · filed 2026-08-11 | 3.19K shares derived: sum of 3 quarters · filed 2026-08-11 | 16.99K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-12 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-12 | 13.80K shares derived: sum of 3 quarters · filed 2026-05-12 | 126.05K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 13.80K shares derived: sum of 2 quarters · filed 2026-03-03 | 126.05K shares derived: sum of 3 quarters · filed 2026-03-03 | 237.18K shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 13.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 126.05K shares derived: sum of 2 quarters · filed 2025-11-06 | 237.18K shares 10-Q · filed 2025-11-06 | 390.86K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 112.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 223.38K shares 10-Q · filed 2025-08-06 | 377.06K shares derived: sum of 3 quarters · filed 2025-08-06 | 257.71K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 111.13K shares 10-Q · filed 2025-05-12 | 264.81K shares derived: sum of 2 quarters · filed 2025-05-12 | 145.46K shares derived: sum of 3 quarters · filed 2025-05-12 | 407.03K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 153.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 34.33K shares derived: sum of 2 quarters · filed 2025-03-19 | 295.90K shares derived: sum of 3 quarters · filed 2025-03-19 | 390.49K shares 10-K · filed 2025-03-19 |
| 2024-09-30 | -119.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 142.22K shares derived: sum of 2 quarters · filed 2024-11-13 | 236.81K shares 10-Q · filed 2024-11-13 | 236.81K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 261.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 356.16K shares 10-Q · filed 2024-08-12 | 356.16K shares derived: sum of 3 quarters · filed 2024-08-12 | 369.82K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 94.59K shares 10-Q · filed 2024-05-14 | 94.59K shares derived: sum of 2 quarters · filed 2024-05-14 | 108.25K shares derived: sum of 3 quarters · filed 2024-05-14 | 149.46K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 13.66K shares derived: sum of 2 quarters · filed 2024-03-28 | 54.87K shares derived: sum of 3 quarters · filed 2024-03-28 | 55.67K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 13.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 54.87K shares derived: sum of 2 quarters · filed 2023-11-09 | 55.67K shares 10-Q · filed 2023-11-09 | 61.83K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 41.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 42.01K shares 10-Q · filed 2023-08-09 | 48.17K shares derived: sum of 3 quarters · filed 2023-08-09 | |
| 2023-03-31 | 802.00 shares 10-Q · filed 2023-05-05 | 6.96K shares derived: sum of 2 quarters · filed 2023-05-05 | ||
| 2022-12-31 | 6.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 6.79K shares 10-K · filed 2023-03-16 | ||
| 2022-09-30 | 634.00 shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |